Troxel T R, Gadberry M S, Wallace W T, Kreider D L, Shockey J D, Colburn E A, Widel P, Nicholson I
University of Arkansas Cooperative Extension Service, Little Rock 72203, USA.
J Anim Sci. 2001 Oct;79(10):2558-64. doi: 10.2527/2001.79102558x.
Experiments were conducted to compare clostridial antibody response of beef heifers that do and do not develop injection-site lesions, evaluate long-term antibody response of a single- and multiple-dose toxoid, and evaluate the ability of a clostridial toxoid to elicit an active antibody response in newborn calves. In Exp. 1, 37 weaned heifers were vaccinated (d 0) with a clostridial vaccine (Alpha-7, 2 mL, s.c.). Serum samples were collected on d 0, 28, 56, 84, and 112 to determine clostridial antibody titers. On d 28, heifers were visually inspected and palpated for injection-site lesions. The percentage of heifers that developed lesions was 64.9%. Lesioned heifers had elevated antibody titers for Clostridium chauvoei (CC) on d 28 (P < 0.08) and 84 (P < 0.07) compared with non-lesioned heifers. Clostridium sordellii (CS) and perfringens type D (CPD) antibody titers were greater in lesioned heifers than in non-lesioned heifers on d 28 and 56. In Exp. 2, long-term antibody response of Alpha-7 (A7) and Ultrabac 7 (UB7) was investigated in stocker heifers. The A7 heifers (n = 15) received one 2-mL vaccination (d 0), and the UB7 heifers (n = 15) received a 5-mL vaccination on d 0 and 28. Blood samples were collected on d 0, 28, 56, 84, 112, 140, and 180. Clostridium chauvoei, CPD, and Cl. novyi (CN) antibody titers from the A7 heifers were greater than those from the UB7 heifers on d 28. Due to the second UB7 injection, CC, CS, CN, and Cl. perfringens type C (CPC) antibody titers were greater in UB7 heifers than in A7 heifers on d 56. By d 112, titers were not different, and by d 140 all antibody titers were below detectable levels. In Exp. 3, 58 pregnant, mature, crossbred cows were vaccinated with A7 before calving. At birth, calves were carefully observed to ensure consumption of colostrum. Calves were blocked according to parturition date, and calves in each block were randomly allocated to receive A7 (s.c. at 3 +/- 3 d of age) or remain unvaccinated controls. Calves were bled at the time of vaccination (d 0) and on d 28, 56, 84, and 112. Antibody titers for CC, CPC, and CPD were elevated on d 0 and decreased throughout the experimental period (P < 0.01), but no titer differences (P > 0.10) were detected between treatment groups on any of the days sampled. These data indicated that antibody titers against clostridial diseases are enhanced when injection-site lesions develop. One injection of Alpha-7 seemed to provide the same length of protection as two injections of Ultrabac 7.
进行了多项实验,以比较出现和未出现注射部位病变的肉用小母牛的梭菌抗体反应,评估单剂量和多剂量类毒素的长期抗体反应,并评估梭菌类毒素在新生犊牛中引发活性抗体反应的能力。在实验1中,37头断奶小母牛在第0天用梭菌疫苗(Alpha-7,2毫升,皮下注射)进行接种。在第0、28、56、84和112天采集血清样本,以测定梭菌抗体滴度。在第28天,对小母牛进行目视检查和触诊,以检查注射部位病变。出现病变的小母牛比例为64.9%。与未出现病变的小母牛相比,出现病变的小母牛在第28天(P<0.08)和第84天(P<0.07)的产气荚膜梭菌(CC)抗体滴度升高。在第28天和第56天,出现病变的小母牛的索氏梭菌(CS)和D型产气荚膜梭菌(CPD)抗体滴度高于未出现病变的小母牛。在实验2中,研究了Alpha-7(A7)和Ultrabac 7(UB7)在育肥牛中的长期抗体反应。A7组小母牛(n=15)在第0天接受一次2毫升接种,UB7组小母牛(n=15)在第0天和第28天分别接受5毫升接种。在第0、28、56、84、112、140和180天采集血样。在第28天,A7组小母牛的产气荚膜梭菌、CPD和诺维氏梭菌(CN)抗体滴度高于UB7组小母牛。由于UB7进行了第二次接种,在第56天,UB7组小母牛的CC、CS、CN和C型产气荚膜梭菌(CPC)抗体滴度高于A7组小母牛。到第112天,滴度没有差异,到第140天,所有抗体滴度均低于可检测水平。在实验3中,58头怀孕的成年杂交母牛在产犊前用A7进行接种。出生时,仔细观察犊牛以确保其摄入初乳。根据分娩日期对犊牛进行分组,每个组中的犊牛被随机分配接受A7(在3±3日龄时皮下注射)或作为未接种疫苗的对照。在接种时(第0天)以及第28、56、84和112天对犊牛进行采血。CC、CPC和CPD的抗体滴度在第0天升高,并在整个实验期间下降(P<0.01),但在任何采样日,治疗组之间均未检测到滴度差异(P>0.10)。这些数据表明,当出现注射部位病变时,针对梭菌病的抗体滴度会增强。一次注射Alpha-7似乎提供了与两次注射Ultrabac 7相同长度的保护。